Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:46:18.558Z.
Calculation as of: 2026-10-06T13:46:18.558Z.
Quote observation: 2026-10-06T13:45:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3daf5633c8ac25837d6b7f560b0674bc697d9f6607e17ed58c514225f564db96
PEG RATIO
N/A
Cronos Group Inc.
Market Cap
$1.23B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Cronos Group Inc. (CRON) | $1.23B | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.23B | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.17B | N/A |
| Kardigan, Inc. (KARD)vs › | $1.29B | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.14B | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.13B | N/A |
PEG Ratio
N/A
P/E Ratio
18.1
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
